Bukwang Pharmaceutical Reports 78.3% Drop in Net Profit for Second Quarter

Bukwang Pharmaceutical (003000) announced on July 21 that its net profit for the second quarter of 2026 fell 78.3% compared to the same period in 2025. Consolidated revenue increased 33.8% year-over-year to 569.88 billion won, while operating income decreased 30.0% to 14.9 billion won. Net profit declined to 13.87 billion won from 63.94 billion won in the prior-year period. The company's half-year cumulative revenue reached 1.0476 trillion won, with net profit at 25.49 billion won, marking a 59.4% decrease from the same period in 2025. The results are based on K-IFRS standards and may differ from final figures due to lack of external audit. As of December 2025, Bukwang Pharmaceutical's consolidated assets totaled 476.3 billion won, with net profit at 124 billion won.